Logo image of NTBL

NOTABLE LABS LTD (NTBL) Stock Fundamental Analysis

NASDAQ:NTBL - Nasdaq - IL0012002452 - Common Stock - Currency: USD

0.2479  -0.09 (-27.68%)

After market: 0.2456 0 (-0.93%)

Fundamental Rating

1

Taking everything into account, NTBL scores 1 out of 10 in our fundamental rating. NTBL was compared to 551 industry peers in the Biotechnology industry. NTBL may be in some trouble as it scores bad on both profitability and health. NTBL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NTBL had negative earnings in the past year.
In the past year NTBL has reported a negative cash flow from operations.
NTBL had negative earnings in each of the past 5 years.
NTBL had a negative operating cash flow in each of the past 5 years.
NTBL Yearly Net Income VS EBIT VS OCF VS FCFNTBL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of NTBL (-152.09%) is worse than 86.15% of its industry peers.
With a Return On Equity value of -232.90%, NTBL is not doing good in the industry: 71.23% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -152.09%
ROE -232.9%
ROIC N/A
ROA(3y)-70.94%
ROA(5y)-62.1%
ROE(3y)-91.91%
ROE(5y)-81.59%
ROIC(3y)N/A
ROIC(5y)N/A
NTBL Yearly ROA, ROE, ROICNTBL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

NTBL has a Gross Margin of 37.70%. This is in the better half of the industry: NTBL outperforms 76.91% of its industry peers.
In the last couple of years the Gross Margin of NTBL has declined.
The Profit Margin and Operating Margin are not available for NTBL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-8.21%
NTBL Yearly Profit, Operating, Gross MarginsNTBL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

3

2. Health

2.1 Basic Checks

NTBL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NTBL has more shares outstanding
NTBL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NTBL has a worse debt to assets ratio.
NTBL Yearly Shares OutstandingNTBL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
NTBL Yearly Total Debt VS Total AssetsNTBL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

NTBL has an Altman-Z score of -16.80. This is a bad value and indicates that NTBL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NTBL (-16.80) is worse than 84.55% of its industry peers.
NTBL has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
NTBL has a Debt to Equity ratio (0.03) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -16.8
ROIC/WACCN/A
WACC10.75%
NTBL Yearly LT Debt VS Equity VS FCFNTBL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 2.77 indicates that NTBL has no problem at all paying its short term obligations.
NTBL has a Current ratio of 2.77. This is in the lower half of the industry: NTBL underperforms 68.56% of its industry peers.
A Quick Ratio of 2.77 indicates that NTBL has no problem at all paying its short term obligations.
NTBL has a worse Quick ratio (2.77) than 67.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.77
NTBL Yearly Current Assets VS Current LiabilitesNTBL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.56% over the past year.
NTBL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.79%.
Measured over the past years, NTBL shows a very negative growth in Revenue. The Revenue has been decreasing by -12.08% on average per year.
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.52%
Revenue 1Y (TTM)-34.79%
Revenue growth 3Y-30.41%
Revenue growth 5Y-12.08%
Sales Q2Q%N/A

3.2 Future

NTBL is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -63.21% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-81.59%
EPS Next 2Y-63.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NTBL Yearly Revenue VS EstimatesNTBL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
NTBL Yearly EPS VS EstimatesNTBL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NTBL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTBL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTBL Price Earnings VS Forward Price EarningsNTBL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTBL Per share dataNTBL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A cheap valuation may be justified as NTBL's earnings are expected to decrease with -63.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.21%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTBL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOTABLE LABS LTD

NASDAQ:NTBL (10/22/2024, 8:00:02 PM)

After market: 0.2456 0 (-0.93%)

0.2479

-0.09 (-27.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2024-08-14/amc
Earnings (Next)11-12 2024-11-12/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners16.5%
Ins Owner Change0%
Market Cap2.39M
Analysts80
Price Target9.18 (3603.11%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.38%
Min EPS beat(2)-25.98%
Max EPS beat(2)-4.77%
EPS beat(4)0
Avg EPS beat(4)-294.73%
Min EPS beat(4)-1133.4%
Max EPS beat(4)-4.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-31.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-27.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.65
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-6.91
EYN/A
EPS(NY)-3.63
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.75
OCFYN/A
SpS0.03
BVpS0.74
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -152.09%
ROE -232.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.7%
FCFM N/A
ROA(3y)-70.94%
ROA(5y)-62.1%
ROE(3y)-91.91%
ROE(5y)-81.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.15%
GM growth 5Y-8.21%
F-Score1
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.83%
Cap/Sales 25.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.77
Altman-Z -16.8
F-Score1
WACC10.75%
ROIC/WACCN/A
Cap/Depr(3y)72.79%
Cap/Depr(5y)45.66%
Cap/Sales(3y)111.54%
Cap/Sales(5y)70.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.52%
EPS Next Y-81.59%
EPS Next 2Y-63.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-34.79%
Revenue growth 3Y-30.41%
Revenue growth 5Y-12.08%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.33%
OCF growth 3YN/A
OCF growth 5YN/A